Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology

International Journal of Andrology

Volumn 33, Issue 3, 2010, Pages 489-499

  Justulin Jr , Luis A ^a   Acquaro, Carolina ^b   Carvalho, Robson F ^b   Silva, Maeli Dal Pai ^b   Felisbino, Sérgio L ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Collagen; Doxazosin; Finasteride; Matrix metalloproteinases; Prostate

Indexed keywords

ANDROSTANOLONE; COLLAGEN FIBER; DOXAZOSIN MESYLATE; FINASTERIDE; GELATINASE A; GELATINASE B; MESSENGER RNA; TESTOSTERONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; EPITHELIUM CELL; FUNCTIONAL MORPHOLOGY; GENE EXPRESSION REGULATION; IMMUNOREACTIVITY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE VENTRAL LOBE; PROTEIN EXPRESSION; RAT; STROMA CELL; TESTOSTERONE BLOOD LEVEL; WISTAR RAT; ZYMOGRAPHY;

ANDROGENS; ANIMALS; CELL PROLIFERATION; DIHYDROTESTOSTERONE; DOXAZOSIN; EPITHELIAL CELLS; EXTRACELLULAR MATRIX; FINASTERIDE; MALE; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RATS; RATS, WISTAR; RNA, MESSENGER; TESTOSTERONE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77951928765     PISSN: 01056263     EISSN: 13652605     Source Type: Journal    
DOI: 10.1111/j.1365-2605.2009.00963.x     Document Type: Article

References (57)

1. Aimes, R. T. Quigley, J. P. (1995) Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. Journal of Biological Chemistry 270, 5872 5876.
2. Austin, P. F., Cook, B. L., Niederhoff, R. A., Manson, S. R., Coplen, D. E. Weintraub, S. J. (2004) Inhibition of mitogenic signaling and induction of apoptosis in human bladder smooth muscle cells treated with doxazosin. Journal of Urology 172, 1662 1665.
3. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72, 248 254.
4. Bruni-Cardoso, A., Vilamaior, P. S., Taboga, S. R. Carvalho, H. F. (2008) Localized matrix metalloproteinase (MMP)-2 and MMP-9 activity in the rat ventral prostate during the first week of postnatal development. Histochemistry and Cell Biology 129, 805 815.
5. Caine, M., Pfau, A. Perlberg, S. (1976) The use of alpha-adrenergic blockers in benign prostatic obstruction. British Journal of Urology 48, 255 263.
6. Carson, C. Rittmaster, R. (2003) The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61, 2 7.
7. Corradi, L. S., Góes, R. M., Carvalho, H. F. Taboga, S. R. (2004) Inhibition of 5-alpha-reductase activity induces stromal remodeling and smooth muscle de-differentiation in adult gerbil ventral prostate. Differentiation 72, 198 208.
8. Duivenvoorden, W. C. M., Hirte, H. W. Singh, G. (1999) Transforming growth factor 1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metabolizing cancer cells. Clinical Experimental Metastasis 17, 27 34.
9. Felisbino, S. L., Justulin Junior, L. A., Carvalho, H. F. Taboga, S. R. (2007) Epithelial-stromal transition of MMP-7 immunolocalization in the rat ventral prostate following bilateral orchiectomy. Cell Biology International 31, 1173 1178.
10. Fernando, M. A. Heaney, A. P. (2005) Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas. Molecular Endocrinology 19, 3085 3096.
11. Festuccia, C., Angellucci, A., Gravina, G. L., Villanova, I., Teti, A., Abini, A. Bologna, M. (2000) Osteoblast-derived TGF-1 modulates matrix degrading protease expression and activity in prostate cancer cells. International Journal Cancer 85, 407 415.
12. Fleisch, M. C., Maxwell, C. A. Barcellos-Hoff, M. H. (2006) The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs. Endocrine-Related Cancer 13, 379 400.
13. Foster, H. E. Jr., Yono, M., Shin, D., Takahashi, W., Pouresmail, M., Afiatpour, P. Latifpour, J. (2004) Effects of chronic administration of doxazosin on alpha1-adrenoceptors in the rat prostate. Journal of Urology 172, 2465 2470.
14. Furuya, S., Kumamoto, Y., Yokoyama, E., Tsukamoto, T., Izumi, T. Abiko, Y. (1982) Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. Journal of Urology 128, 836 839.
15. Garrison, J. B., Shaw, Y. J., Chen, C. S. Kyprianou, N. (2007) Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Research 67, 11344 11352.
16. Glassman, D. T., Chon, J. K., Borkowski, A., Jacobs, S. C. Kyprianou, N. (2001) Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate 46, 45 51.
17. Griffiths, K. Denis, L. J. (2000) Exploitable mechanisms for the blockade of androgenic action. Prostate Supplement 10, 43 51.
18. Huang, X. Lee, C. (2003) Regulation of stromal proliferation, growth arrest, differentiation and apoptosis in benign prostatic hyperplasia by TGF-beta. Frontiers in Bioscience 8, 740 749.
19. Huynh, H. (2002) Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. International Journal of Oncology 20, 1297 1303.
20. Incorvaia, L., Badalamenti, G., Rini, G., Arcara, C., Fricano, S., Sferrazza, C., Di Trapani, D., Gebbia, N. Leto, G. (2007) MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Research 27, 1519 1525.
21. Junqueira, L. C., Bignolas, G. Brentabi, R. R. (1979) Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochemical Journal 11, 447 455.
22. Justulin, L. A. Jr., Delella, F. K. Felisbino, S. L. (2008) Doxazosin reduces cell proliferation and increases collagen fibers in rat prostatic lobes. Cell and Tissue Research 332, 171 183.
23. Keledjian, K., Garrison, J. B. Kyprianou, N. (2005) Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. Journal of Biochemistry & Cell Biology 94, 374 388.
24. Kyprianou, N. (2003) Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. Journal of Urology 169, 1520 1525.
25. Kyprianou, N. Benning, C. M. (2000) Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Research 60, 4550 4555.
26. Kyprianou, N. Isaacs, J. T. (1987) Biological significance of measurable androgen levels in the rat ventral prostate following castration. Prostate 10, 313 324.
27. Kyprianou, N. Isaacs, J. T. (1988) Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122, 552 562.
28. Kyprianou, N., Litvak, J. P., Borkowski, A., Alexander, R. Jacobs, S. C. (1998) Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. Journal of Urology 159, 1810 1815.
29. Li, B. Y., Liao, X. B., Fujito, A., Thrasher, J. B., Shen, F. Y. Xu, P. Y. (2007) Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells. Asian Journal Andrology 9, 41 50.
30. Liao, X., Thrasher, J. B., Pelling, J., Holzbeierlein, J., Sang, Q. X. Li, B. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656 1663.
31. Lichtinghagen, R., Musholt, P. B., Lein, M., Römer, A., Rudolph, B., Kristiansen, G., Hauptmann, S., Schnorr, D., Loening, S. A. Jung, K. (2002) Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. European Urology 42, 398 406. (Pubitemid 35175803)
32. Limaye, A. M., Desai, K. V., Chavalmane, A. K. Kondaiah, P. (2008) Regulation of mRNAs encoding MMP-9 and MMP-2, and their inhibitors TIMP-1 and TIMP-2 by androgens in the rat ventral prostate. Molecular Cellular Endocrinology 294, 10 18.
33. Lobaccaro, J. M., Boundon, C., Lechevallier, E., Mottet, N., Rebillard, X., Lumbroso, S., Gibelin, B. Sultan, C. (1996) Effect of finasteride (Proscar) on the proliferation of cultured epithelial and stromal cells from normal and hyperplastic human prostates. Cell and Molecular Biology 42, 511 518.
34. Lokeshwar, B. L. (1999) MMP inhibition in prostate cancer. Annals of the New York Academy of Sciences 878, 271 289.
35. Mannello, F., Luchetti, F., Falcieri, E. Papa, S. (2005) Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 10, 19 24.
36. McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L. Jr., Dixon, C. M., Kusek, J. W. et al. (2003) Medical Therapy of Prostatic Symptoms (MTOPS) Research Group.The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. The New England Journal of Medicine 349, 2387 2398.
37. McVary, K. T. (2007) A review of combination therapy in patients with benign prostatic hyperplasia. Clinical Therapeutics 29, 387 398.
38. Mitropoulos, D., Papakonstantinou, E., Aletras, A. J., Kalinderis, N., Zervas, A., Hatzichristou, D. Karakiulakis, G. (2007) Terazosin modifies the content of glycosaminoglycans and the activity of matrix metalloproteinase 2 in the rat ventral prostate. European Urology 2007 (51 447 456.
39. Mol, A. J., Geldof, A. A., Meijer, G. A., van der Poel, H. G. van Moorselaar, R. J. (2007) New experimental markers for early detection of high-risk prostate cancer: role of cell-cell adhesion and cell migration. Journal of Cancer Research and Clinical Oncology 133, 687 695.
40. Morgia, G., Falsaperla, M., Malaponte, G., Madonia, M., Indelicato, M., Travali, S. Mazzarino, M. C. (2005) Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urological Research 33, 44 50.
41. Nagase, H. Woessner, J. F. Jr. (1999) Matrix metalloproteinases. Journal of Biological Chemistry 274, 21491 21494.
42. Nemeth, J. A. Lee, C. (1996) Prostatic ductal system in rats: regional variation in stromal organization. Prostate 28, 124 128.
43. Powell, W. C., Domann, F. E. Jr., Mitchen, J. M., Matrisian, L. M., Nagle, R. B. Bowden, G. T. (1996) Matrilysin expression in the involuting rat ventral prostate. Prostate 29, 159 168.
44. Prahalada, S. R., Keenan, K. P., Hertzog, P. R., Gordon, L. R., Peter, C. P., Soper, K. A., Zwieten, M. J. Bokelman, D. L. (1994) Qualitative and quantitative evaluation of prostatic histomophology in rats following chronic treatment with Finasterida, a 5-alpha reductase inhibitor. Urology 43, 680 685.
45. Prahalada, S. R., Rhodes, L., Grossman, S. J., Heggan, D., Keenan, K. P., Cukierski, M. A., Hoe, C. M., Berman, C. van Zwieten, M. J. (1998) Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasterida, a 5-alpha reductase inhibitor. Prostate 35, 157 164.
46. Ra, H. J. Parks, W. C. (2007) Control of matrix metalloproteinase catalytic activity. Matrix Biology 26, 587 596.
47. Rittmaster, R. S., Manning, A. P., Wright, A. S., Thomas, L. N., Whitefield, S., Norman, R. W., Lazier, C. B. Rowden, G. (1995) Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5α-reductase inhibitor finasteride. Endocrinology 136, 741 748.
48. Sáez, C., González-Baena, A. C., Japón, M. A., Giráldez, J., Segura, D. I., Miranda, G., Rodríguez-Vallejo, J. M., González-Esteban, J. Torrubia, F. (1998) Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-beta receptor expression. Prostate 37, 84 90.
49. Schuster, N. Krieglstein, K. (2002) Mechanisms of TGF-beta-mediated apoptosis. Cell and Tissue Research 307, 1 14.
50. Sehgal, I. Thompson, T. C. (1999) Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. Molecular Biology of the Cell 10, 407 416.
51. Sternlicht, M. D. Werb, Z. (2001) How matrix metalloproteinases regulate cell behaviour. Annual Review Cellular and Developmental Biology 17, 463 516.
52. Wilson, M. J. (1995) Proteases in prostate development, function, and pathology. Microscopy Research and Technique 30, 305 318.
53. Wilson, M. J., Strasser, M., Vogel, M. M. Sinha, A. A. (1991) Calcium-dependent and calcium-independent gelatinolytic proteinase activities of the rat ventral prostate and its secretion: characterization and effect of castration and testosterone treatment. Biology of Reproduction 44, 776 785.
54. Woessner, J. F. Jr. (1994) The family of matrix metalloproteinases. Annals New York Academy of Sciences 732, 11 21.
55. Yamashita, A., Hayashi, N., Sugimura, Y., Cunha, G. R. Kawamura, J. (1996) Influence of diethylstilbestrol, leuprolelin (a luteinizing hormone-releasing hormone analog), finasteride (a 5 alpha-reductase inhibitor), and castration on the lobar subdivisions of the rat prostate. Prostate 29, 1 14.
56. Zhu, B. Kyprianou, N. (2005) Transforming growth factor beta and prostate cancer. Cancer Treatment and Research 126, 157 173.
57. Zucker, S., Cao, J. Chen, W. T. (2000) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19, 6642 6650.